Effects of Vitamin B3 in Patients With Ataxia Telangiectasia

Phase 2

Completed

• Conditions: ATM Gene Mutation; Ataxia Telangiectasia
• Interventions: Dietary Supplement: Vitamin B3

• Registration Number: NCT03962114
• Lead Sponsor: Radboud University Medical Center

Brief Summary

This clinical trial investigates the effects of nicotinamide riboside (vitamin B3) on the disease course of patients with ataxia telangiectasia.

Patients will be treated during four consecutive months with nicotinamide riboside (25mg/kg/day), followed by a washout period of two months.

Main study parameters/endpoints: Ataxia, dysarthria, quality of life, laboratory parameters.

Detailed Description

Rationale: Ataxia Telangiectasia (A-T) is an autosomal recessively inherited neurodegenerative disorder, with a high cancer risk, that also affects the immune and respiratory system. Therapy for A-T is restricted to symptomatic treatment including rehabilitation care, combined with infection prevention and treatment, and screening for pulmonary dysfunction and malignancies. A-T is caused by mutations in the ATM gene. The ATM protein plays a pivotal role in more than 100 different biochemical processes, among which cellular energy metabolism, cell signaling, and DNA repair. Nicotinamide adenine dinucleotide (NAD+) is an essential molecule in many of these processes and studies have shown that NAD+ deficiency plays a role in disease mechanisms underlying DNA repair disorders such as A-T. NAD+ is available in food, but can also be synthesized in the body from its precursors nicotinamide, nicotinic acid, and nicotinamide riboside (NR), as a group called "vitamin B3". Treatment of experimental A-T animal models with NR showed beneficial effects. The aim of this study is to investigate whether treatment with NR during a period of six months may have positive effects on the disease course of patients with A-T.

Objective: To investigate the effects of NR on the disease course of patients with ataxia telangiectasia.

Study design: Single center, interventional, explorative, open-label proof of concept study.

Study population: Patients with A-T (age \>2 years).

Intervention (if applicable): Patients will be treated with nicotinamide riboside (25mg/kg/day), during four consecutive months, followed by a washout period of two months.

Main study parameters/endpoints: Ataxia, dysarthria, quality of life, laboratory parameters.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2019-03
• Study Start: 2019-03-18
• Study First Submitted: 2019-04-11
• Study First Submitted QC: 2019-05-22
• Study First Posted: 2019-05-23
• Primary Completion: 2019-12-01
• Study Completion: 2020-03-01
• Last Update Submitted: 2022-07-21
• Last Update Posted: 2022-07-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• A-T patients who visit our outpatient clinic.
• Genetically confirmed diagnosis of A-T by the identification of pathogenic mutations of the ATM gene.
• Age ≥ 2 years or older and bodyweight ≥ 12 Kg.
• Informed consent.

Read More

Exclusion Criteria

• Additional medical condition or illness that impair the patient's ability to participate in the study (e.g. actual treatment of a malignancy, active infection, poorly controlled diabetes mellitus, hypertension, organ failure, clinically significant hematological or biochemical abnormalities different from the usual abnormalities in A-T)
• Elevated serum transaminases (> 2 times upper limit of normal)
• Participation in another interventional study at start of the study or during the study
• Pregnancy.
• Breast feeding.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Intervention group	Vitamin B3	treatment with vitamin B3

Primary Outcome Measures

Name	Time	Method
Ataxia, 9-hole pegboard test.	change from baseline -1 month - 4 months - 6 months	Changes in fastes time of the 9-hole pegboard test will be measured.
Dysarthria, Radboud dysarthria assesment (RDA)	change from baseline -1 month - 4 months - 6 months	Changes in maximum performance tasks and severity of dysarthria will be measured.
Ataxia, ICARS (International Cooperative Ataxia Rating Scale)	change from baseline -1 month - 4 months - 6 months	Changes in the total score will be measured.
Ataxia, SARA (Scale of the assesment and rating of ataxia)	change from baseline -1 month - 4 months - 6 months	Changes in the total score will be measured.

Secondary Outcome Measures

Name	Time	Method
Laboratory measurements	change from baseline -1 month - 4 months - 6 months	Results will be summarized descriptively, with abnormal and clinically notable values/findings being identified
Intelligibility, Intelligibility in Context Scale (ICS)	change from baseline -1 month - 4 months - 6 months	Changes in the total score of the Intelligibility in Context Scale (ICS), will be measured.
Fatigue, Visual Analogous Scale (VAS)	change from baseline -1 month - 4 months - 6 months	Changes in the total VAS score will be measured.
Quality of life questionnaire EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L)	change from baseline -1 month - 4 months - 6 months	Changes in the total quality of life score will be measured.

Trial Locations

Locations (1)

Radboudumc; 🇳🇱 Nijmegen, Netherlands